Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

177Lu-octreotide, DOTA(0)-Tyr(3)- × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Specimen Handling 408 Magnetic Resonance Spectroscopy 333 pembrolizumab 280 Biopsy 225 Carboplatin 218 Cisplatin 182 Nivolumab 164 Cyclophosphamide 164 Gemcitabine 160 Paclitaxel 148 Bevacizumab 120 Radiotherapy 111 atezolizumab 98 Docetaxel 94 Dexamethasone 94 Oxaliplatin 89 venetoclax 87 fludarabine 87 Rituximab 83 durvalumab 81 Fluorouracil 81 Radiation 80 Pemetrexed 79 Doxorubicin 78 Ipilimumab 74 Prednisone 73 Taxes 71 Leucovorin 66 X-Rays 64 Lenalidomide 64

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡